The College of Pharmacy is home to world-renowned researchers who are leading in their fields of study.
Sharyn Baker, PharmD, PhD
The research in Dr. Baker’s lab is focused on identifying mechanisms of drug resistance in Acute Myeloid Leukemia and the preclinical evaluation of new therapeutic strategies to treat or circumvent resistance. These studies utilize molecular biology, pharmacology and next generation sequencing techniques and in vitro/in vivo models of cancer. Her research also involves characterizing the clinical pharmacology of investigational and approved anticancer agents in laboratory models and cancer patients to improve drug therapy. Dr. Baker’s lab works in a collaborative team environment so that the most promising preclinical findings are translated to clinical trials, and in turn, clinical observations provide feedback to inform preclinical studies.
James Fuchs, PhD
The research in Dr. Fuchs' lab designs and prepares novel molecules for therapeutic applications against cancer and infectious diseases. His lab utilizes fundamental chemical knowledge and synthetic methodology to facilitate the process of drug discovery and development through the generation of biological probe molecules, the synthesis of lead compounds and the optimization of drug properties.
Shuiying Hu, PhD
Many chemotherapeutic agents can cause quality-of-life impacting neurological side effects. The incidence of chemotherapy-induced peripheral neuropathy (CIPN) is particularly high with agents such as paclitaxel and oxaliplatin, occurring in up to 80% of patients receiving such agents. There are currently no effective strategies for prevention of CIPN, and rationally designed intervention studies are needed to better address this gap. Dr. Hu’s research interests are focused on the development of transport modulators that could be used in conjunction with neurotoxic chemotherapy:
- To understand drug transporter regulation mechanism.
- To determine the role of drug transporters on anticancer agents induced inter-individual pharmacokinetic variability, antitumor efficacy and drug-drug interaction.
- To evaluate contribution of solute carrier to chemotherapy-induced CIPN.
- To develop preclinical and clinical studies with potential implications to ameliorate the incidence and severity of debilitating side effects of cancer drugs.
A. Douglas Kinghorn, PhD, DSc
The research in Dr. A. Douglas Kinghorn’s lab deals with the extraction, purification, and characterization of the chemical structures of biologically active substances of tropical plants. Examples of the use to society of these lead compounds are as potential cancer chemotherapeutic and chemopreventive agents, therapies for the tropical infectious disease leishmaniasis, and as sweetening and taste-modifying components of foods and beverages.
Blake R. Peterson, PhD
Dr. Peterson’s research group is working to discover small molecules that affect the proliferation of cancer cells and associated immune cells that support malignancy. To find these compounds, the Peterson laboratory creates fluorescent molecular probes that are designed to facilitate drug discovery. These probes are used in conjunction with phenotypic drug discovery methods to identify both anticancer agents with novel mechanisms of action and their molecular targets. To optimize and evaluate these compounds, they use synthetic organic chemistry, medicinal chemistry, and chemical biology approaches. These strategies, in conjunction with assays based on confocal microscopy, flow cytometry, and other fluorescence-based techniques, provide a platform for the identification of new therapeutic agents.
Cynthia Carnes, PharmD, PhD
Dr. Carnes’ research is focused on furthering our understanding of abnormal heart rhythms (arrhythmias) with the goal of optimizing treatment. A particular focus of her program is understanding the underpinnings of arrhythmias occurring during heart failure. A second aspect of Dr. Carnes’ arrhythmia research program is developing and validating processes to improve clinical pharmacy services for patients on long-term antiarrhythmic medication therapy.
Dr. Carnes is also interested in junior faculty development with an emphasis on providing foundations for research independence in clinical and translational research. This work is supported in her role as director of the KL2 scholars program at the Ohio State Center for Clinical and Translational Science.
Karl Werbovetz, PhD
The primary focus of research in Dr. Werbovetz’s group is the discovery and development of new drug candidates and drug delivery strategies against leishmaniasis, a protozoan parasitic disease that mainly affects developing areas of the world. The Werbovetz lab is involved in the synthesis of new drug candidates as well as the in vitro and in vivo antileishmanial evaluation of molecules made in house and by collaborators. The lab is also interested in pursuing other interesting biological activities displayed by molecules from the lab.
Mark Mitton-Fry, PhD
Dr. Mitton-Fry’s research team is dedicated to inventing cures for multidrug-resistant bacterial infections. The lab focuses primarily on the discovery of Novel Bacterial Topoisomerase Inhibitors (NBTIs), compounds which can overcome resistance by means of their differentiated binding mode. The lab uses the tools of synthetic medicinal chemistry to design and prepare innovative new molecules, and collaborates broadly to evaluate their biological, pharmaceutical, and toxicological properties.